Wenxing Qin

Wenxing Qin

Auto-generated profile, based on publicly available information

Wenxing Qin

Department of Medical Oncology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen, China; Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
WQWenxing Qin
Wenxing Qin
YDYuran Duan
Yuran Duan
ZHZhiqiang Hu
Zhiqiang Hu
YHYueru Hou
Yueru Hou
TWTing Wen
Ting Wen
DXDaqian Xu
Daqian Xu
Hypoxia induces immunosuppressive phenotypes in tumor cells even in the presence of cytosolic DNA accumulation. The mechanisms by which tumor cells suppress hypoxia-induced cGAS-STING activation for immune evasion remain largely unclear. Here, we demonstrate that hypoxic stimulation induces JNK1/2-mediated S151 phosphorylation of phosphoenolpyruvate carboxykinase 1 (PCK1), a rate-limiting enzyme in gluconeogenesis. This phosphorylation triggers the interaction between PCK1 and cGAS. The PCK1 associated with cGAS competitively consumes GTP, a substrate shared by both PCK1 and cGAS. Consequently, PCK1 inhibits GTP-dependent cGAS activation and subsequent STING-promoted immune cell infiltration and activation in the tumor microenvironment, leading to promoted tumor growth in mice. The blockade of PCK1 function, in combination with anti–PD-1 antibody treatment, exhibits an additive therapeutic effect on tumor growth. Additionally, PCK1 S151 phosphorylation is inversely correlated with cGAS-STING activation in human breast cancer specimens and patient survival. These findings reveal a novel regulation of cGAS-STING pathway and uncover the metabolic control of immune response in tumor cells.

24 January 2026 in Cancer Biome and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YLYouli Li
Youli Li
YCYang Chen
Yang Chen
YMYuxin Mu
Yuxin Mu
XXXuemei Xiu
Xuemei Xiu
WQWenxing Qin
Wenxing Qin
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer with high recurrence and early metastasis. Unlike hormone receptor-positive or HER2-positive cancers, TNBC lacks targeted therapies, and standard chemotherapy often yields limited and transient responses, making treatment challenging. The tumor microenvironment (TME) plays a central role in TNBC progression, immune evasion, and therapy resistance. It comprises multiple cellular components, tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), tumor-infiltrating lymphocytes (TILs), and myeloid-derived suppressor cells (MDSCs), as well as structural and signaling elements such as the extracellular matrix (ECM), growth factors, and cytokines. Interactions among these components create an immunosuppressive, pro-tumorigenic milieu that supports cancer cell survival, invasion, and metastasis. Targeting the TME has emerged as a promising therapeutic strategy. Immunotherapies, particularly immune checkpoint inhibitors (ICIs), can restore antitumor immunity by reversing T cell exhaustion and mitigating immune suppression. Response rates remain variable, leading to the exploration of combination approaches that pair ICIs with chemotherapy, radiotherapy, or TME-modulating agents to enhance efficacy. Direct targeting of TME components, including CAFs, TAMs, MDSCs, and ECM remodeling enzymes, is also being developed to disrupt the supportive tumor niche and enhance drug delivery. This review provides a comprehensive overview of the TNBC TME, emphasizing its role in tumor progression and therapy resistance, and summarizes current and emerging strategies to target the TME. By clarifying complex cellular and molecular interactions, these approaches aim to sensitize tumors to therapy, prevent metastasis, and support the development of more effective, personalized treatments for TNBC.